An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

被引：0
|
作者：
Xue, Bin [1 ]
Liu, Yifan [1 ]
Zhang, Min [1 ]
Xiao, Gangfeng [1 ,2 ]
Luo, Xiu [1 ]
Zhou, Lili [1 ]
Ye, Shiguang [1 ]
Lu, Yan [1 ]
Qian, Wenbin [3 ]
Wang, Li [4 ]
Li, Ping [1 ]
Liang, Aibin [1 ]
机构：
[1] Tongji Univ, Sch Med, Shanghai Tongji Hosp, Dept Hematol, Shanghai 200065, Peoples R China
[2] Ningbo No 2 Hosp, Dept Hematol, Ningbo 315010, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Hematol, Hangzhou 310009, Zhejiang, Peoples R China
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Hematol, Shanghai 200001, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2025年 / 138卷 / 01期
基金：
国家重点研发计划; 上海市自然科学基金; 中国国家自然科学基金;
关键词：
D O I：
10.1097/CM9.0000000000003343
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：108 / 110
页数：3
相关论文
共 50 条
  • [1] An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
    Xue Bin
    Liu Yifan
    Zhang Min
    Xiao Gangfeng
    Luo Xiu
    Zhou Lili
    Ye Shiguang
    Lu Yan
    Qian Wenbin
    Wang Li
    Li Ping
    Liang Aibin
    中华医学杂志英文版, 2025, 138 (01)
  • [2] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Iqbal, Madiha
    Jagadeesh, Deepa
    Chavez, Julio
    Khurana, Arushi
    Rosenthal, Allison
    Craver, Emily
    Epperla, Narendranath
    Li, Zhuo
    Isufi, Iris
    Awan, Farrukh T.
    Dholaria, Bhagirathbhai R.
    Maakaron, Joseph E.
    Sandoval-Sus, Jose D.
    Mishra, Rahul
    Saha, Aditi
    Annunzio, Kaitlin
    Bhaskar, Shakthi T.
    Sumransub, Nuttavut
    Fijalka, Andrew
    Ivanov, Stanislav A.
    Lin, Yi
    Kharfan-Dabaja, Mohamed A.
    BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 211 - 216
  • [3] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Madiha Iqbal
    Deepa Jagadeesh
    Julio Chavez
    Arushi Khurana
    Allison Rosenthal
    Emily Craver
    Narendranath Epperla
    Zhuo Li
    Iris Isufi
    Farrukh T. Awan
    Bhagirathbhai R. Dholaria
    Joseph E. Maakaron
    Jose D. Sandoval-Sus
    Rahul Mishra
    Aditi Saha
    Kaitlin Annunzio
    Shakthi T. Bhaskar
    Nuttavut Sumransub
    Andrew Fijalka
    Stanislav A. Ivanov
    Yi Lin
    Mohamed A. Kharfan-Dabaja
    Bone Marrow Transplantation, 2024, 59 : 211 - 216
  • [4] CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
    Jacobson, Caron A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 328 - +
  • [5] Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report
    Huang, Chen
    Zhang, Hui-Chao
    Ho, Jin-Yuan
    Liu, Rui-Xia
    Wang, Lin
    Kuang, Na
    Zheng, Mei-Rong
    Liu, Li-Hong
    Li, Jian-Qiang
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [6] Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Iqbal, Madiha
    Khurana, Arushi
    Chavez, Julio
    Rosenthal, Allison C.
    Li, Zhuo
    Craver, Emily
    Aditi, Saha
    Epperla, Narendranath
    Annunzio, Kaitlin
    Awan, Farrukh T.
    Isufi, Iris
    Dholaria, Bhagirathbhai
    Bhaskar, Shakthi
    Maakaron, Joseph
    Sumransub, Nuttavut
    Fijalka, Andrew
    Sandoval-Sus, Jose
    Ivanov, Stanislav
    Lin, Yi
    Kharfan-Dabaja, Mohamed A.
    BLOOD, 2022, 140 : 10396 - 10398
  • [7] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
    Ernst, Moritz
    Oeser, Annika
    Besiroglu, Burcu
    Caro-Valenzuela, Julia
    Aziz, Mohamed Abd El
    Monsef, Ina
    Borchmann, Peter
    Estcourt, Lise J.
    Skoetz, Nicole
    Goldkuhle, Marius
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [8] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [9] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 13 - 15
  • [10] Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
    Tian, Linyan
    Li, Cheng
    Sun, Juan
    Zhai, Yixin
    Wang, Jinhuan
    Liu, Su
    Jiang, Yanan
    Wu, Wenqi
    Xing, Donghui
    Lv, Yangyang
    Guo, Jing
    Xu, Hong
    Sun, Huimeng
    Li, Yuhang
    Li, Lanfang
    Zhao, Zhigang
    FRONTIERS IN IMMUNOLOGY, 2023, 13
12345